Abbvie Inc. Common Stock (ABBV) 69.34 $ABBV Is Gilead

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2015 at 12:08 AM

Abbvie Inc. Common Stock (ABBV) 69.34 $ABBV

Is Gilead Sciences About to Make an Acquisition?
ESTMZ - Mon Jul 27, 2:24PM CDT
Gilead Sciences (GILD) reports its FQ2 ’15 results after the closing bell tomorrow. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.77 and a revenue target of $7.540B. Wall...
SPY: 206.79 (-1.21), GILD: 110.54 (-2.29), ALXN: 198.10 (-2.89), ABBV: 69.34 (+1.26), NDAQ: 51.17 (-0.72)

4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 12:51PM CDT
Let's turn the spotlight this World Hepatitis Day on some hepatitis-focused companies poised to grow.
ESRX: 91.10 (-1.19), GILD: 110.54 (-2.29), ACHN: 8.28 (-0.41), MRK: 56.99 (-0.42), ABBV: 69.34 (+1.26), BMY: 64.30 (-1.68), NVS: 101.54 (-0.26)

Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings
at The Street - Mon Jul 27, 11:42AM CDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
GILD: 110.54 (-2.29), ABBV: 69.34 (+1.26)

3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 309.43 (+9.40), ILMN: 217.27 (-3.83), ABBV: 69.34 (+1.26)

Company News for July 27, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Companies in the News are: ABBV,COG,XRX,JCI
COG: 26.44 (-0.06), XRX: 10.62 (-0.32), ABBV: 69.34 (+1.26), JCI: 44.00 (-0.24)

European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
Business Wire - Mon Jul 27, 6:00AM CDT
--Empliciti is poised to be the first-in-class SLAMF7-directed immunostimulatory antibody
ABBV: 69.34 (+1.26), BMY: 64.30 (-1.68)

AbbVie (ABBV) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Fri Jul 24, 2:44PM CDT
The following AbbVie (ABBV) conference call took place on July 24, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 69.34 (+1.26)

AbbVie's Investments Begin Kicking In
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 24, 2:20PM CDT
Source: AbbVie. AbbVie Inc .'s investments to offset the impact of lost sales tied to expiring patent protection on Humira in 2017 include a big push into hepatitis C and its $21 billion acquisition of the cancer drugmaker Pharmacyclics earlier...
ABBV: 69.34 (+1.26)

TECHNIVIE(TM) (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S.
PR Newswire - Fri Jul 24, 1:00PM CDT
AbbVie (NYSE: ABBV), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) in combination with ribavirin (RBV) for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection who do not have cirrhosis. TECHNIVIE is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. The approval of TECHNIVIE marks an important advancement in providing this historically difficult-to-treat population of HCV patients an opportunity for a cure. Virologic cure is defined as a sustained virologic response (SVR), which is when the virus is no longer detectable in the patient's blood 12 weeks after treatment (SVR12).1 TECHNIVIE is not recommended for use in patients with moderate hepatic impairment (Child-Pugh .
ABBV: 69.34 (+1.26)

Biogen's Big-Volume Plunge Marks End Of 5-Year Run
at Investor's Business Daily - Fri Jul 24, 12:26PM CDT
Biogen's (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company also cut its...
BIIB: 309.43 (+9.40), VRX: 257.30 (+5.38), LLY: 84.15 (-0.57), ABBV: 69.34 (+1.26), BMY: 64.30 (-1.68), CELG: 132.56 (-2.34)

Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed
at Investor's Business Daily - Fri Jul 24, 10:44AM CDT
Big-cap biotech Biogen (BIIB) beat Q2 earnings estimates Friday, but it lowered its guidance and reported failure in a clinical trial, sending its stock plummeting. Meanwhile, big pharma AbbVie (ABBV) reported a steadier quarter and affirmed its...
JNJ: 98.28 (-0.87), BIIB: 309.43 (+9.40), ABBV: 69.34 (+1.26)

AbbVie (ABBV) Stock Sliding on Earnings Miss
at The Street - Fri Jul 24, 10:33AM CDT
AbbVie (ABBV) shares are tumbling after the drug maker reported weaker-than-expected fiscal 2015 second quarter earnings results.
ABBV: 69.34 (+1.26)

AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 24, 9:39AM CDT
Although AbbVie's (ABBV) second quarter earnings surpassed expectations, the revenue miss is disappointing.
NLNK: 50.97 (-0.87), LGND: 102.55 (+0.46), AMAG: 65.07 (-5.37), ABBV: 69.34 (+1.26)

AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 8:16AM CDT
AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues
ABBV: 69.34 (+1.26)

AbbVie Reports Second-Quarter 2015 Financial Results
PR Newswire Europe - Fri Jul 24, 6:58AM CDT
- Reports Second-Quarter Adjusted EPS of $1.08, Up 31.7 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06 (Reports GAAP EPS of $0.83)
ABBV: 69.34 (+1.26)

American Airlines Earnings and New Home Sales Will Wrap up Busy Week
at The Street - Thu Jul 23, 7:15PM CDT
Biogen, AbbVie and Spirit Airlines are also reporting results on Friday, and the PMI flash manufacturing index is notable on the economic calendar.
BIIB: 309.43 (+9.40), SAVE: 59.78 (-0.55), DAL: 43.93 (-0.17), AAL: 40.14 (+0.51), ABBV: 69.34 (+1.26), LUV: 35.09 (+0.09)

Will AbbVie (ABBV) Surprise on Earnings Again in Q2? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jul 23, 4:48PM CDT
Investor focus this quarter will remain on AbbVie's (ABBV) Humira, Viekira and Imbruvica.
CYTK: 7.19 (+0.06), JNJ: 98.28 (-0.87), MDCO: 33.39 (-0.43), ABBV: 69.34 (+1.26)

Stocks Extend Losses; Amazon, Visa Headline After-Hours Action
at Investor's Business Daily - Thu Jul 23, 4:06PM CDT
Sellers were in the stock market again Thursday as Wall Street digested another avalanche of second-quarter earnings reports. At the close, the Dow Jones industrial average had lost 0.7%, the S&P 500 fell 0.6% and the Nasdaq had shed 0.5%....
BIIB: 309.43 (+9.40), UA: 96.43 (+0.38), AMZN: 531.41 (+1.99), VRX: 257.30 (+5.38), SAVE: 59.78 (-0.55), V: 73.86 (-0.94), CYBR: 59.83 (-3.18), ABBV: 69.34 (+1.26), FTNT: 47.10 (-0.89)

Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 227.09 (-0.91), ABBV: 69.34 (+1.26), CELG: 132.56 (-2.34)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truss Financial Tackles Home Equity Closing Delays

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

ROKFORM’s Signal Card: A Wallet Tracker for All

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Charter Next Generation Unveils Gen 2 MDO-PE Films

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

NYSE Texas Redefines the U.S. Capital Markets Landscape

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

IWP and VYRE Unveil 'The Plug' for VBNGtv Content

Bringing Capital and Content Under One Roof There's something in the air as Itibari-Waynne & Partners (IWP) team up with the VYRE Network to crank out a fresh slate of content for VYRE Business News Global (VBNGtv). This partnership ain't just another splash in the buzzy world of digital media; it's like merging Wall Street with Hollywood. IWP, prepping to go full...

Northern Jet Names Veteran Matthew Harris as CEO

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...